ADIL:NSD-Adial Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.38

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.38M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic agents for the treatment of alcohol use disorders. Its lead product is AD04, a selective serotonin-3 antagonist that has completed Phase IIb clinical trials for the treatment of nausea and emesis. The company was founded in 2010 and is based in Charlottesville, Virginia.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD75.50B 48.39 36.24
REGN Regeneron Pharmaceuticals, Inc

N/A

USD62.07B 30.02 20.75
SGEN Seattle Genetics, Inc

N/A

USD28.53B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

N/A

USD24.72B 10.98 9.43
MRNA Moderna, Inc

N/A

USD24.07B N/A N/A
INCY Incyte Corporation

N/A

USD22.68B 47.64 35.20
BMRN BioMarin Pharmaceutical Inc

N/A

USD21.81B 193.21 115.90
GMAB Genmab A/S

N/A

USD21.51B 59.03 6.26
ALNY Alnylam Pharmaceuticals, Inc

N/A

USD17.42B N/A N/A
BGNE BeiGene, Ltd

N/A

USD15.19B N/A N/A

ETFs Containing ADIL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -42.74% 11% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.74% 11% F 12% F
Trailing 12 Months  
Capital Gain -22.91% 34% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -22.91% 34% F 34% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -21.10% 37% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.10% 37% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 26.14% 89% B+ 62% D-
Risk Adjusted Return -80.72% 27% F 14% F
Market Capitalization 0.02B 7% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.59 62% D- 36% F
Price / Cash Flow Ratio -3.14 35% F 70% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -94.73% 35% F 14% F
Return on Invested Capital -142.38% 14% F 5% F
Return on Assets -57.61% 14% F 5% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.04 97% A+ 97% A+
Short Percent 0.32% 92% A- 88% B+
Beta 0.03 94% A 93% A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.